中国寄生虫学与寄生虫病杂志

• 论著 • 上一篇    下一篇

恶性疟原虫二氢乳清酸脱氢酶抑制剂体外诱导恶性疟原虫耐药的实验研究

周洪昌*, 张慧, 李小余, 郭跃, 姚韵靓, 王莎   

  1. 湖州师范学院医学院病原生物与免疫学教研室分子及转化医学团队, 湖州313000
  • 出版日期:2017-08-30 发布日期:2017-09-14

In vitro induction of drug resistance of Plasmodium falciparum by an inhibitor of its dihydroorotate dehydrogenase

ZHOU Hong-chang*, ZHANG Hui, LI Xiao-yu, GUO Yue, YAO Yun-liang, WANG Sha   

  1. Program of Molecular and Translational Medicine, Department of Pathogen Biology and Immunology, School of Medicine, Huzhou University, Huzhou 313000, China
  • Online:2017-08-30 Published:2017-09-14

摘要:

目的 分析恶性疟原虫二氢乳清酸脱氢酶(Plasmodium falciparum dihydroorotate dehydrogenase, PfDHODH)抑制剂(二氢噻吩酮类化合物, 编号50, 以下简称PfDHODH抑制剂50)对体外培养恶性疟原虫的作用特点及其诱导耐药的可能机制。 方法 恶性疟原虫氯喹敏感株(3D7株)和氯喹抗性株(Dd2株)同步化培养后分为不加药对照组、环状体期加药组和大滋养体期加药组, 药物终浓度为80 nmol/L。分别在同步化后0 h(环状体期)、24 h(大滋养体期)、42 h涂薄血膜片镜检; 通过逐步加大药物浓度的方法, 体外诱导产生耐药虫株, 3个月后经有限稀释培养, 获得单克隆耐药虫株。采用SYBR Green Ⅰ染料法检测各耐药虫株对PfDHODH抑制剂50、氯喹和青蒿素的半数抑制浓度(IC50); PCR扩增各耐药虫株Pfdhodh基因并测序, 分析其突变情况。 结果 与不加药对照组相比, 环状体期加药组恶性疟原虫从滋养体到裂殖体的发育受到明显抑制, 大滋养体期加药组恶性疟原虫呈现明显的空泡化, 核质密度大大降低。通过体外诱导并经有限稀释培养, 获得44株PfDHODH抑制剂50的单克隆耐药虫株, 其中, 母本为Dd2、3D7的耐药虫株分别为24和20株, 它们对PfDHODH抑制剂50的IC50分别为(2.284±0.096)和(0.678±0.018)μmol/L, 较母本虫株的(0.018±0.002)和(0.015±0.002)μmol/L分别提高了近130倍和50倍; 对氯喹和青蒿素的IC50分别为(0.011±0.002)、(0.014±0.004)和(0.013±0.003)、(0.012±0.001)μmol/L; 与母本Dd2虫株相比, Dd2耐药虫株对氯喹的IC50从(0.072±0.002)μmol/L下降为(0.011±0.002)μmol/L。测序分析结果显示, 23株Dd2来源的耐药虫株PfDHODH蛋白氨基酸序列发生了G181D的点突变, 另有1株除G181D的点突变外, 还产生了K32N的点突变; 3D7来源的耐药虫株未发现相应突变。 结论 体外诱导获得PfDHODH抑制剂50的单克隆耐药虫株, G181D的点突变可能是导致恶性疟原虫高水平耐受PfDHODH抑制剂50的重要分子机制。

关键词: 恶性疟原虫, 二氢乳清酸脱氢酶, 抑制剂, 耐药

Abstract:

Objective To explore the effects of an inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) (a dihydrothiophenone derivative, referred to as PfDHODH inhibitor 50) on cultured P. falciparum parasites of 3D7 (sensitive to chloroquine) and Dd2 strains (resistant to chloroquine), and investigate the underlying mechanisms. Methods The highly synchronized parasites were divided into three groups, negative control group, PfDHODH inhibitor 50 group at the ring stage and PfDHODH inhibitor 50 group at the trophozoite stage. The final concentration of the inhibitor was 80 nmol/L. Giemsa staining was performed at 0 (the ring stage), 24 (the ring stage) and 42 h after synchronization. Drug resistance was induced by gradually increasing the PfDHODH inhibitor 50 concentration. After three months the drug-resistant clone strains were obtained by limiting dilution. The half maximal inhibitory concentration (IC50) values of each strain in the presence of PfDHODH inhibitor 50, chloroquine or artemisinin were measured by the SYBR Green Ⅰ method. The Pfdhodh gene was amplified by PCR and sequenced to examine mutations. Results Compared to the control group, PfDHODH inhibitor 50 addition at the ring stage significantly inhibited the development of parasites from trophozoites to schizonts, while that added at the trophozoite stage induced obvious vacuolization and decreased density of cytoplasm and nucleus. Forty-four PfDHODH inhibitor 50-resistant strains were obtained, in which 24 strains were derived from Dd2 and 20 were derived from 3D7. Their IC50 values to PfDHODH inhibitor 50 were (2.284±0.096) and (0.678±0.018) μmol/L, respectively, which were increased by about 130 and 50 folds compared with their maternal strains Dd2 and 3D7. The IC50 values of Dd2-derived resistant strains to chloroquine and artemisinin were (0.011±0.002) and (0.014±0.004) μmol/L, respectively, and those of 3D7-derived resistant strains were (0.013±0.003) and (0.012±0.001) μmol/L, respectively. Compared with the maternal Dd2 strain, the IC50 of resistant strains to chloroquine decreased from (0.072±0.002) μmol/L to (0.011±0.002) μmol/L. Sequencing results revealed G181D point mutation in the PfDHODH protein sequence in 23 Dd2-derived resistant strains, G181D and K32N point mutations in 1 Dd2-derived resistant strain, while no PfDHODH mutation was found for 3D7-derived resistant strains. Conclusion PfDHODH inhibitor 50-resistant strains were obtained. The G181D mutation in PfDHODH may be the main molecular mechanism for the resistance to PfDHODH inhibitor 50.

Key words:  Plasmodium falciparum, Dihydroorotate dehydrogenase, Inhibitor, Drug resistance